Article

NYU, Pfizer launch sexual health referral network

The New York University School of Medicine and Pfizer, Inc., have launched the Men's Sexual Health Referral Network, an online listing of health care professionals who treat male sexual dysfunction and related disorders.

The New York University School of Medicine and Pfizer, Inc., have launched the Men's Sexual Health Referral Network, an online listing of health care professionals who treat male sexual dysfunction and related disorders.

MSHRN provides potential sexual health patients with easy access to a network of highly qualified health care professionals and an online resource in which they can research regional experts. Men can also find tips on how to speak with their existing doctors or an MSHRN health care professional about sexual health.

Prospective patients may visit www.SexualHealthDoctors.com and enter their zip code to locate a nearby physician or counselor.

Related Videos
Helen L. Bernie, DO, MPH, answers a question during a Zoom video interview
Kate H. Kraft, MD, MHPE, FACS, FAAP, answers a question during a Zoom video interview
John P. Mulhall, MD, answers a question during a Zoom video interview
Hailey Frye answers a question during a Zoom video interview
Related Content
FDA approves PET imaging product Gozellix for prostate cancer
March 20th 2025

FDA approves PET imaging product Gozellix for prostate cancer

Hannah Clarke
Gozellix – after radiolabeling with 68Ga – is indicated for PET imaging of PSMA positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and those who have suspected recurrence based on an elevated serum prostate-specific antigen level.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Nadofaragene firadenovec maintains safety, efficacy in real-world population
March 20th 2025

Nadofaragene firadenovec maintains safety, efficacy in real-world population

Mark D. Tyson, MD, MPH Jacob A. Moyer, BS Hannah Clarke
"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Real-world data reaffirm oncologic benefits of BLC for NMIBC
March 19th 2025

Real-world data reaffirm oncologic benefits of BLC for NMIBC

Hannah Clarke
"These data support current AUA/SUO guidelines recommending BLC usage in patients with NMIBC to increase detection and decrease recurrence," says Stephen B. Williams, MD, MBA, MS, FACS, FACHE.
Tiopronin delayed-release tablets available in US for patients with cystinuria
March 18th 2025

Tiopronin delayed-release tablets available in US for patients with cystinuria

Hannah Clarke
This announcement follows the successful launch of generic tiopronin delayed-release tablets last year.
© 2025 MJH Life Sciences

All rights reserved.